|Trade names||Zestoretic, Prinzide, others|
|Defined daily dose||not established|
|AHFS/Drugs.com||Multum Consumer Information|
Lisinopril/hydrochlorothiazide, sold under the trade name Zestoretic among others, is a combination of the medications lisinopril, an ACE inhibitor, and hydrochlorothiazide, a diuretic. It is used to treat high blood pressure. Typically, it becomes an option once a person is doing well on the individual components. It is taken by mouth.
Common side effects include dizziness, headache, cough, and feeling tired. Severe side effects may include angioedema and low blood pressure. Use during pregnancy may harm the baby.
The combination was approved for medical use in the United States in 1989. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In the United States the wholesale cost per dose is less than US$0.05 as of 2018[update]. In the United Kingdom it costs the NHS about GB£0.40 per dose as of 2017[update]. In 2017, it was the 44th most commonly prescribed medication in the United States, with more than 16 million prescriptions.
The defined daily dose is not established.
Society and culture
In the United States the wholesale cost per dose is less than US$0.05 as of 2018[update].In the United Kingdom it costs the NHS about GB£0.40 per dose as of 2017[update]. In 2017, it was the 44th most commonly prescribed medication in the United States, with more than 16 million prescriptions.
- ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 9 September 2020.
- ↑ 2.0 2.1 2.2 2.3 "Hydrochlorothiazide and lisinopril Uses, Side Effects & Warnings". Drugs.com. Cerner Multum. Archived from the original on 28 June 2019. Retrieved 26 December 2018.
- ↑ 3.0 3.1 3.2 3.3 British national formulary : BNF 74 (74 ed.). British Medical Association. 2017. p. 166. ISBN 978-0857112989.
- ↑ 4.0 4.1 4.2 "Lisinopril and Hydrochlorothiazide - FDA prescribing information, side effects and uses". Drugs.com. Solco Healthcare LLC. Archived from the original on 18 April 2019. Retrieved 26 December 2018.
- ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ 6.0 6.1 "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services. Archived from the original on 19 December 2018. Retrieved 22 December 2018.
- ↑ 7.0 7.1 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ↑ 8.0 8.1 "Hydrochlorothiazide; Lisinopril - Drug Usage Statistics". ClinCalc. Archived from the original on 11 April 2020. Retrieved 11 April 2020.
- "Hydrochlorothiazide mixture with Lisinopril". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 12 April 2020. Retrieved 12 April 2020.
- Pages using duplicate arguments in template calls
- Use dmy dates from September 2019
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs that are a combination of chemicals
- Articles containing potentially dated statements from 2018
- All articles containing potentially dated statements
- Articles containing potentially dated statements from 2017
- Antihypertensive agents
- Combination drugs
- AstraZeneca brands
- World Health Organization essential medicines
- All stub articles
- Antihypertensive agent stubs